Animal studies have shown that INH-RIF-induced oxidative injury can be prevented by
supporting the cellular antioxidant defense mechanism by N-acetylcysteine (NAC). However,
there are few published data and large sample sizes regarding the protective effect of NAC
against hepatotoxicty induced by anti-TB drugs in humans, to our knowledge.
Therefore, the investigators designed a clinical trial with the aim to see whether NAC could
protect against anti-TB drug-induced hepatotoxicity (DIH)